Compatibility Study of Moxifloxacin Hydrochloride with Various Excipients and Formulation of its Spheroids

Objective: The aim of current study is to investigate compatibility study of moxifloxacin hydrochloride with various excipients and development of formulation of its spheroids. Methods: Different analytical instruments such as Bruker Advance Neo 500 MHz NMR spectrometer, Fourier transform infrared spectroscopy (FTIR) Spectrum RX 1, Differential scanning calorimetry (DSC) [DSC-Q20, TA Instruments, (New Castle Delaware, U.S)], and IR (Perkin Elmer spectrum 400 USA FTIR.) and UV spectrometer (Lab India) have been used. Moxifloxacin hydrochloride (MFX.HCl) was managed as gift sample from Galpha Laboratories Ltd., New Delhi. Methyl cellulose, lactose, sodium carboxy methylcellulose, magnesium stearate (MgS), hydroxypropyl methylcellulose (HPMC), microcrystalline cellulose (MCC) PH 200, MCC PH 101, mannitol, starch, potassium hydrogen phosphate, di-sodium hydrogen phosphate, sodium chloride, sodium hydroxide, and HCl were obtained from Loba chemie Pvt. Ltd., Mumbai and Central drug house, New Delhi. The acetonitrile (HPLC grade), and methanol (HPLC grade), were bought from Thermo-fisher scientific India Pvt. Ltd. Results: MFX.HCl was characterized by melting point, DSC, FTIR, Nuclear magnetic resonance (NMR), and UV spectrometer. Compatibility study of MFX.HCl was done by use of different analytical techniques. Preformulation investigations were carried out by UV validation, solubility testing for drug. Five batches of MFX.HCl were formulated with the use of diluent and HPMC as binder in the formulation. Further, pellets of MFX.HCl was characterized. The in vitro drug release of MFX.HCl with batches B2, B3, B4 and B5 displayed 55.77%, 66.83%, 73.49% and 95.32% drug release within the first 30 minutes. Release kinetic study of developed pellets for moxifloxacin.HCl was also investigated for batches i.e. B2 to B5. Conclusion: MFX.HCl was founded compatible with used excipients. From the findings of the MFX.HCl pellet characterization investigations, batches B2, B3, and B5 had high or excellent flow characteristics, whereas batch B1 had a fair flow nature. The in vitro drug release of MFX.HCl of batches B2, B3, B4, and B5 revealed 55.77%, 66.83%, 73.49%, and 95.32% drug release within the first 30 minutes, respectively. The drug content for batches B1–B5 ranged from 98.7 to 100.2%. Because B5 had less HPMC than the previous batches, it displayed the maximum release. A release kinetic analysis of the drug's produced pellets was also conducted for batches B2-B5 of MFX.HCl. The MFX.HCl was released using the Hixon Crowell model in batch B2, the Higuchi model in batch B4, the Zero Order Kinetics model in batch B3, and the First Order Kinetic Model in batch B5.